NOVARTIS

NOVARTIS logo
🇨🇭Switzerland
Ownership
Public, Private
Established
1996-01-01
Employees
76K
Market Cap
$242.6B
Website
https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Fluvastatin in the Therapy of Acute Coronary Syndrome

Phase 4
Completed
Conditions
First Posted Date
2005-09-15
Last Posted Date
2010-07-16
Lead Sponsor
Novartis
Target Recruit Count
1000
Registration Number
NCT00171275
Locations
🇨🇿

Novartis, Praha, Czech Republic

Study Comparing Full-dose Radiotherapy Versus Reduced Dose in the Management of Bone Metastasis in Patients With Breast Cancer Receiving Zoledronic Acid

First Posted Date
2005-09-15
Last Posted Date
2023-08-18
Lead Sponsor
Novartis
Target Recruit Count
116
Registration Number
NCT00172029
Locations
🇹🇷

Novartis Investigative Site, Trabzon, Turkey

Efficacy and Safety of Valsartan Versus Placebo on Exercise Tolerance in Patients With Heart Failure

First Posted Date
2005-09-15
Last Posted Date
2016-11-18
Lead Sponsor
Novartis
Target Recruit Count
150
Registration Number
NCT00171106
Locations
🇨🇭

Novartis Pharmaceuticals, Basel, Switzerland

Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients

Phase 2
Completed
Conditions
First Posted Date
2005-09-14
Last Posted Date
2009-11-19
Lead Sponsor
Novartis
Target Recruit Count
40
Registration Number
NCT00166725
Locations
🇮🇹

Orbassano, Orbassano, Italy

The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

Phase 4
Completed
Conditions
First Posted Date
2005-09-12
Last Posted Date
2023-12-14
Lead Sponsor
Novartis
Target Recruit Count
55
Registration Number
NCT00154323

Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients

First Posted Date
2005-09-12
Last Posted Date
2013-11-13
Lead Sponsor
Novartis
Target Recruit Count
300
Registration Number
NCT00154310
Locations
🇨🇭

Novartis Pharma AG, Basel, Switzerland

🇨🇭

Novartis Investigational Sites, Bern, Switzerland

Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis

Phase 3
Completed
Conditions
First Posted Date
2005-09-12
Last Posted Date
2012-05-21
Lead Sponsor
Novartis
Target Recruit Count
1200
Registration Number
NCT00154219
Locations
🇬🇧

Various Sites, Multiple Cities, United Kingdom

🇺🇸

For US Site Information, contact Novartis Pharmaceuticals, East Hanover, New Jersey, United States

© Copyright 2024. All Rights Reserved by MedPath